Shares of Clearside Biomedical Inc (NASDAQ:CLSD) hit a new 52-week low on Wednesday . The company traded as low as $6.50 and last traded at $6.63, with a volume of 17,521 shares changing hands. The stock had previously closed at $6.90.

A number of analysts recently commented on CLSD shares. Stifel Nicolaus started coverage on Clearside Biomedical in a research report on Monday, June 27th. They issued a “buy” rating and a $13.00 price objective for the company. Needham & Company LLC started coverage on Clearside Biomedical in a research report on Tuesday, June 28th. They issued a “buy” rating and a $16.00 price objective for the company. Cowen and Company started coverage on Clearside Biomedical in a research report on Monday, June 27th. They issued an “outperform” rating for the company. Finally, Wedbush started coverage on Clearside Biomedical in a research report on Monday, June 27th. They issued an “outperform” rating and a $28.00 price objective for the company.

The company has a 50 day moving average price of $0.00 and a 200 day moving average price of $0.00. The stock’s market capitalization is $17.65 million.

In related news, major shareholder Venture Advisors Iv S. Hatteras bought 414,286 shares of the business’s stock in a transaction dated Tuesday, June 7th. The stock was purchased at an average cost of $7.00 per share, for a total transaction of $2,900,002.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.

Clearside Biomedical, Inc is a late-stage clinical biopharmaceutical company. The Company is developing drug therapies to treat blinding diseases of the eye. The Company’s product candidates are focused on diseases affecting the retina and choroid, especially diseases associated with macular edema, and are injected into the suprachoroidal space (SCS) adjacent to the choroid, using its SCS Microinjector.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.